Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$24.86 USD
+1.86 (8.09%)
Updated May 9, 2024 04:00 PM ET
After-Market: $24.63 -0.23 (-0.93%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
NTLA 24.86 +1.86(8.09%)
Will NTLA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTLA
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Other News for NTLA
NTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024
Intellia Therapeutics, Inc. (NTLA) Q1 2024 Earnings Call Transcript
Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)